Meeting
2021 ASCO Annual Meeting
A validated model to predict low recurrence risk distinguished by 21-gene recurrence score in hormone receptor-positive invasive breast cancer patients.
Authors
Yasue Tsuchida
Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan
Yasue Tsuchida , Sachiko Ohde , Ryota Nakamura , Yoko Kanada , Sakiko Miura , Masafumi Takimoto , Seigo Nakamura , Naoki Kanomata , Hideko Yamauchi , Naoki Hayashi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 532)
DOI
10.1200/JCO.2021.39.15_suppl.532
Abstract #
532
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Clinical validity of CTS5 for estimating risk of late recurrence in unselected, non-trial patients with early ER+ breast cancer.
First Author: Juliet Richman
First Author: Bent Ejlertsen
Poster
2015 ASCO Annual Meeting
Phase III study of Palbociclib in combination with Exemestane vs. Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006)
First Author: Miguel Martin
Poster
2020 ASCO Virtual Scientific Program
Prognostic and predictive value of ESR1 mutations in postmenopausal metastatic breast cancer (MBC) patients (pts) resistant to aromatase inhibitors (AI), treated with palbociclib (PAL) in combination with endocrine therapy (ET) or capecitabine (CAP) in the PEARL study.
First Author: Miguel Martin